References
- Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2022.
- Sharman JP , Egyed M , Jurczak W ,et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.Lancet.2020;395(10232):1278–1291.
- Sharman JP , Egyed M , Jurczak W ,et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.Leukemia.2022;36(4):1171–1175.
- Gelber RD , Cole BF , Gelber S ,et al. Comparing treatments using quality-adjusted survival: the Q-TWiST method.Am Stat.1995;49:161–169.
- Levy V , Porcher R , Delabarre F ,et al. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.J Clin Epidemiol.2001;54(7):747–754.
- Solem CT , Kwon Y , Shah RM ,et al. Systematic review and benchmarking of quality-adjusted time without symptoms or toxicity (Q-TWiST) in oncology.Expert Rev Pharmacoecon Outcomes Res.2018;18(3):245–253.
- Dolan P. Modeling valuations for EuroQol health states.Med Care.1997;35(11):1095–1108.
- Kosmas CE , Shingler SL , Samanta K ,et al. Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival.Leuk Lymphoma.2015;56(5):1320–1326.
- Revicki DA , Feeny D , Hunt TL ,et al. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data.Qual Life Res.2006;15(3):411–423.
- Le H , Ryan K , Wahlstrom SK ,et al. Oncologist and patient preferences for novel agents in first-line treatment for chronic lymphocytic leukemia: commonalities and disconnects.Patient Prefer Adherence.2021;15:99–110.
- Laurenti L , Gaidano G , Mauro FR ,et al. What are the attributes prioritized in the choice of therapy in chronic lymphocytic leukemia? A patient-physician cross-matching analysis of a discrete choice experiment.Hemasphere.2022;6(9):e771.
- Julious SA , Campbell MJ. Tutorial in biostatistics: sample sizes for parallel group clinical trials with binary data.Stat Med.2012;31(24):2904–2936.
- Sharman JP , Emeribe U , Cai L ,et al. A quality-adjusted survival (Q-TWiST) analysis of acalabrutinib with or without obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia [poster 1083755].Presented at: biennial International Workshop on Chronic Lymphocytic Leukemia.17–20 September 2021;